Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Open Access
- 22 September 2022
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 175, 224-235
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) AntibodiesJAMA Neurology, 2017
- Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapyJournal of Neuroimmunology, 2017
- Neurologic complications of immune checkpoint inhibitorsCurrent Opinion in Neurology, 2016
- Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literatureAnnals of Oncology, 2016
- Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosisClinical Neurology and Neurosurgery, 2014
- Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patientsAnnals of Hematology, 2013
- Herpes simplex encephalitis in patients with cancerJournal of Neuro-Oncology, 2011
- Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agentsHaematologica, 2010
- Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case seriesThe Lancet Neurology, 2010